JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 14, 2025, titled "Press Release".
JBCHEPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
JB Pharma reported Q4 FY25 revenue of INR 949 crores, up 10% YoY, with net profit rising 15% to INR 146 crores. Operating EBITDA grew 15% to INR 240 crores with margins improving 90 basis points to 25.3%. For the full year FY25, revenue grew 12% to INR 3,918 crores, net profit jumped 19% to INR 660 crores, and operating EBITDA crossed INR 1,000 crores for the first time at INR 1,087 crores (up 16%). Domestic formulations were the standout, growing 20% for the year to INR 2,269 crores, while the CDMO business bounced back strongly in the second half. The company also strengthened its balance sheet with net cash rising sharply to INR 689 crores from INR 107 crores a year ago, and ROCE improving to 32% from 27%.
Strong across-the-board results with double-digit revenue and profit growth, margin expansion, and a significantly stronger balance sheet. Domestic franchise momentum and CDMO recovery are positive signals, likely to support positive sentiment in the stock.